These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3517235)

  • 1. Mesulergine in early Parkinson's disease: a double blind controlled trial.
    Dupont E; Mikkelsen B; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J; Orman J; Jansson B
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
    Rascol A; Montastruc JL; Rascol O; Senard JM
    Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
    Ahlskog JE; Wright KF; Muenter MD; Adler CH
    Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
    Dupont E; Andersen A; Boas J; Boisen E; Borgmann R; Helgetveit AC; Kjaer MO; Kristensen TN; Mikkelsen B; Pakkenberg H; Presthus J; Stien R; Worm-Petersen J; Buch D
    Acta Neurol Scand; 1996 Jan; 93(1):14-20. PubMed ID: 8825266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
    Schneider E; Baas H; Fischer PA; Japp G
    J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI; Sadekov RA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.